Evidence supporting the use of: Palmitoylethanolamide (PEA)
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide that has been studied for its anti-inflammatory and neuroprotective properties. There is emerging, but limited, scientific interest in the use of PEA to support or treat Parkinson's Disease (PD). Preclinical studies in animal models of PD indicate that PEA can reduce neuroinflammation and may protect dopaminergic neurons from degeneration, which are key factors in the pathology of PD. Some small human studies and case reports suggest that PEA supplementation may improve certain symptoms of PD, such as pain and rigidity, possibly via its effects on non-neuronal cells (glia) and modulation of the endocannabinoid system.

However, clinical evidence is currently sparse. Randomized controlled trials in humans are lacking, and most available data come from preliminary or open-label studies with small sample sizes and short durations. As a result, while PEA has a plausible scientific rationale and some promising early results, the overall evidence supporting its use in Parkinson's Disease remains weak and inconclusive. Larger, well-designed clinical trials are needed to establish efficacy and safety. Thus, PEA should not be considered a standard or primary treatment for PD, but rather an experimental adjunct under medical supervision.

More about Palmitoylethanolamide (PEA)
More about Parkinson's Disease

Products containing Palmitoylethanolamide (PEA)

We currently have no products on Vitabase that contain this ingredient.